openPR Logo
Press release

Spasticity Treatment Market 2032: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Epidemiology, Statistics, Revenue, Therapies, Treatment, Companies by DelveInsight

03-25-2025 02:28 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Spasticity Treatment Market

Spasticity Treatment Market

(Albany, USA) DelveInsight's "Spasticity Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Spasticity, historical and forecasted epidemiology as well as the Spasticity market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Spasticity market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Spasticity market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Spasticity treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Spasticity market.

Request for a Free Sample Report @ Spasticity Market Forecast - https://www.delveinsight.com/report-store/spasticity-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some facts of the Spasticity Market Report are:
• According to DelveInsight, Spasticity market size is expected to grow at a decent CAGR by 2032.
• Spasticity market size in the 7MM was observed to be ~USD 904 million in 2021.
• Leading Spasticity companies working in the market are Ipsen Biopharmaceuticals, Inc, RVL Pharmaceuticals, Merz Pharmaceuticals, Allergan, Inc, Jazz Pharmaceuticals, Metacel Pharmaceuticals, Piramal, Amneal Pharmaceuticals, Azurity, Daiichi Pharmaceutical Co., Ltd and many others.
• Key Spasticity Therapies expected to launch in the market are Arbaclofen ER, SL-1002, Botulinum neurotoxin, MYOBLOC, SPARC1104, Hyaluronidase, Tizanidine, Moxifloxacin, and many others.
• In January 2025:- Ipsen:- The purpose of the study is to assess the safety and efficacy of increasing doses of IPN10200 with the aim to evaluate the Pharmacodynamics (PD) profile of IPN10200 and to establish the total IPN10200 doses(s) that offer the best efficacy/safety profile when used for the treatment of Adult upper limb (AUL) spasticity.
• In January 2025:- Chongqing Claruvis Pharmaceutical Co., Ltd.:- This is a randomized, double-blind, dose escalation, placebo- and active-controlled parallel-group multi-center phase II study to evaluate the efficacy and safety of Recombinant Botulinum Toxin Type A (YY001) for injection in the treatment of upper limb spasticity in adults.
• In January 2025:- Pacira Pharmaceuticals Inc.:- This multicenter, randomized, double-blind, sham-controlled study is designed to evaluate the efficacy and safety of the iovera° system in subjects with upper extremity spasticity. A total of approximately 132 subjects will be enrolled; 88 subjects will receive treatment with the iovera° system and 44 subjects will receive sham treatment (sham iovera° system treatment).
• On May 2024, AbbVie announced results of a Phase IV, Observational, Non-Interventional, Prospective, Multicenter Study on Botulinum A Toxin (OnabotulinumtoxinA) Use in Mexican Pediatric Population With Spasticity Associated With Cerebral Palsy.
• On March 2024, Ipsen announced results of an integrated Phase I/II, Multicentre, Double-blind, Randomised, Dysport and Placebo-controlled, Dose Escalation and Dose-finding Study to Evaluate the Safety and Efficacy of IPN10200 in the Treatment of Adult Upper Limb Spasticity.
• On December 2023, RVL Pharmaceuticals, Inc announced results of a Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Efficacy of Arbaclofen Extended-Release Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis (Study OS440-3006).

Spasticity Overview
Spasticity is a condition characterized by muscle stiffness and involuntary muscle contractions, which can interfere with movement and coordination. It commonly occurs in individuals with neurological conditions such as multiple sclerosis, cerebral palsy, stroke, or spinal cord injury. Spasticity results from disruptions in the communication between the brain and the muscles, leading to an imbalance of signals that cause muscles to contract excessively. This can manifest as muscle tightness, stiffness, spasms, and difficulty controlling movements.
The severity of spasticity varies among individuals and can range from mild discomfort to severe impairment of mobility and function. It can affect any muscle group but often impacts the limbs, making it challenging to perform daily activities such as walking, reaching, or grasping objects. In addition to physical symptoms, spasticity can also cause pain, discomfort, and fatigue, further affecting quality of life.
Treatment for spasticity aims to alleviate symptoms, improve function, and enhance overall well-being. This may involve a multidisciplinary approach, including physical therapy, occupational therapy, medications, injections (such as botulinum toxin), orthotics, and in some cases, surgical interventions. Management strategies are tailored to individual needs and may evolve over time as symptoms change.
While spasticity can pose significant challenges, advancements in medical understanding and treatment options offer hope for improved outcomes and better quality of life for individuals living with this condition. Ongoing research aims to further enhance our understanding of spasticity mechanisms and develop innovative therapies to effectively manage symptoms and optimize function.

Do you know what will be the Spasticity market share in 7MM by 2032 @ https://www.delveinsight.com/sample-request/spasticity-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Spasticity Market
The Spasticity market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Spasticity market trends by analyzing the impact of current Spasticity therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.
This segment gives a thorough detail of the Spasticity market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Spasticity market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Spasticity market in 7MM is expected to witness a major change in the study period 2019-2032.

Spasticity Epidemiology
The Spasticity epidemiology section provides insights into the historical and current Spasticity patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Spasticity market report also provides the diagnosed patient pool, trends, and assumptions.

Interested to know how the emerging diagnostic approaches will be contributing in increased Spasticity diagnosed prevalence pool? Download report @ Spasticity Treatment Market - https://www.delveinsight.com/report-store/spasticity-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Spasticity Drugs Uptake
This section focuses on the uptake rate of the potential Spasticity drugs recently launched in the Spasticity market or expected to be launched in 2019-2032. The analysis covers the Spasticity market uptake by drugs, patient uptake by therapies, and sales of each drug.

Spasticity Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Spasticity market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Spasticity Pipeline Development Activities
The Spasticity report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Spasticity key players involved in developing targeted therapeutics.

Download report to know which TOP 3 therapies will be capturing the largest Spasticity market share by 2032? Click here @ https://www.delveinsight.com/sample-request/spasticity-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Spasticity Therapeutics Assessment
Major key companies are working proactively in the Spasticity Therapeutics market to develop novel therapies which will drive the Spasticity treatment markets in the upcoming years are Ipsen Biopharmaceuticals, Inc, RVL Pharmaceuticals, Merz Pharmaceuticals, Allergan, Inc, Jazz Pharmaceuticals, Metacel Pharmaceuticals, Piramal, Amneal Pharmaceuticals, Azurity, Daiichi Pharmaceutical Co., Ltd and many others.

Do you know how Arbaclofen ER market launch will be impacting the Spasticity market CAGR? Download sample report @ Spasticity Drugs Market - https://www.delveinsight.com/sample-request/spasticity-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Spasticity Report Key Insights
1. Spasticity Patient Population
2. Spasticity Market Size and Trends
3. Key Cross Competition in the Spasticity Market
4. Spasticity Market Dynamics (Key Drivers and Barriers)
5. Spasticity Market Opportunities
6. Spasticity Therapeutic Approaches
7. Spasticity Pipeline Analysis
8. Spasticity Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Spasticity Market

Table of Contents
1. Key Insights
2. Executive Summary
3. Spasticity Competitive Intelligence Analysis
4. Spasticity Market Overview at a Glance
5. Spasticity Disease Background and Overview
6. Spasticity Patient Journey
7. Spasticity Epidemiology and Patient Population
8. Spasticity Treatment Algorithm, Current Treatment, and Medical Practices
9. Spasticity Unmet Needs
10. Key Endpoints of Spasticity Treatment
11. Spasticity Marketed Products
12. Spasticity Emerging Therapies
13. Spasticity Seven Major Market Analysis
14. Attribute Analysis
15. Spasticity Market Outlook (7 major markets)
16. Spasticity Access and Reimbursement Overview
17. KOL Views on the Spasticity Market
18. Spasticity Market Drivers
19. Spasticity Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer

Trending Reports:
• Androgenetic Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Catheter-related Bloodstream Infections Market: https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-crbsi-market-size-analysis
• Cough Assisted Device Market: https://www.delveinsight.com/report-store/cough-assist-devices-market
• Neuroprosthetics Market: https://www.delveinsight.com/report-store/neuroprosthetics-market-market
• Atherectomy Devices Market: https://www.delveinsight.com/report-store/atherectomy-devices-market
• Central Venous Catheters Market: https://www.delveinsight.com/report-store/central-venous-catheters-market
• Pharma Licensing Services: https://www.delveinsight.com/consulting/licensing-services
• Acoustic Neuroma Market: https://www.delveinsight.com/report-store/acoustic-neuroma-market
• Gaucher Disease Market: https://www.delveinsight.com/report-store/gauchers-disease-market
• Pressure Ulcers Market: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Benefits Of Robotics In Healthcare: https://www.delveinsight.com/blog/robotics-in-healthcare
• Healthcare Due Diligence Services: https://www.delveinsight.com/consulting/due-diligence-services
• Acrocallosal Syndrome Market: https://www.delveinsight.com/sample-request/acrocallosal-syndrome-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Healthcare Competitive Benchmarking: https://www.delveinsight.com/consulting/competitive-benchmarking-services
• Hearing Implants Market: https://www.delveinsight.com/report-store/hearing-implants-market
• Wound Irrigation Systems Market: https://www.delveinsight.com/report-store/wound-irrigation-systems-market?utm_source=Medgadget&utm_medium=pressrelease&utm_campaign=kupr
• Anterior Cruciate Ligament Injuries Market: https://www.delveinsight.com/report-store/anterior-cruciate-ligament-injuries-epidemiology-forecast
• Molecular Glue Trials: https://www.delveinsight.com/report-store/molecular-glues-competitive-landscape
• Healthcare Subscription Models: https://www.delveinsight.com/blog/subscription-model-in-healthcare
• Pulse Oximeter Market: https://www.delveinsight.com/report-store/pulse-oximeters-market
• Vascular Access Devices Market: https://www.delveinsight.com/report-store/vascular-access-device-market
• Cardiorenal Syndrome Market: https://www.delveinsight.com/report-store/myocardial-infarction-market
• Trigeminal Neuralgia Market Size: https://www.delveinsight.com/report-store/tuberous-sclerosis-complex-market
• Acute Intermittent Porphyria Market: https://www.delveinsight.com/report-store/acute-intermittent-porphyria-market
• Anti-cd274 Pd-l1 Antibody Pipeline: https://www.delveinsight.com/report-store/anti-cd274-pd-l1-antibody-pipeline-insight
• Healthcare Consulting: https://www.delveinsight.com/consulting
• Healthcare Partner Identification Services: https://www.delveinsight.com/consulting/partner-identification-services
• Hereditary Spastic Paraplegias Market: https://www.delveinsight.com/report-store/hereditary-spastic-paraplegias-market
• Molecular Glue Market: https://www.delveinsight.com/report-store/molecular-glues-market-forecast

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Spasticity Treatment Market 2032: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Epidemiology, Statistics, Revenue, Therapies, Treatment, Companies by DelveInsight here

News-ID: 3936768 • Views:

More Releases from DelveInsight Business Research

Von Willebrand Disease Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates
Von Willebrand Disease Market Insights Highlight Expanding Outlook Till 2034, De …
DelveInsight's "Von Willebrand Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Von Willebrand Disease, historical and forecasted epidemiology as well as the Von Willebrand Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Von Willebrand Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Von Willebrand Disease
Global Artificial Kidney Market to reach USD 6.09 billion by 2032 at a CAGR of 12.80% by 2032, Evaluates DelveInsight
Global Artificial Kidney Market to reach USD 6.09 billion by 2032 at a CAGR of 1 …
According to DelveInsight's analysis, The growing demand for artificial kidneys is primarily fueled by the increasing prevalence of kidney failure and end-stage renal disease (ESRD), alongside a rising incidence of contributing factors such as diabetes, hypertension, and an aging global population. These trends are driving the need for advanced and efficient renal care technologies. Moreover, the expanding preference for home-based dialysis solutions, combined with continuous technological innovations and frequent product
Global Bladder Scanners Market to grow at a CAGR of 6.12% by 2032, Evaluates DelveInsight
Global Bladder Scanners Market to grow at a CAGR of 6.12% by 2032, Evaluates Del …
According to DelveInsight's analysis, The growing prevalence of urinary disorders such as incontinence, urinary retention, and overactive bladder especially among the aging population continues to drive demand for bladder scanners. The increasing preference for non-invasive and efficient diagnostic tools is further propelling market growth, as bladder scanners provide a safe, quick, and accurate alternative to traditional catheterization. Their expanding use across hospitals, clinics, and home care settings highlights their clinical
Global Transdermal Drug Delivery Devices Market to reach USD 121,798.76 million by 2032 at a CAGR of 6.91% by 2032, Evaluates DelveInsight
Global Transdermal Drug Delivery Devices Market to reach USD 121,798.76 million …
According to DelveInsight's analysis, The rising incidence of chronic diseases, along with the growing adoption of advanced third-generation transdermal drug delivery systems, is substantially driving the global market's growth. DelveInsight's "Transdermal Drug Delivery Devices Market Insights, Competitive Landscape and Market Forecast-2032" report provides the current and forecast market outlook, forthcoming device innovation, challenges, market drivers and barriers. The report also covers the major emerging products and key Transdermal Drug Delivery Devices

All 5 Releases


More Releases for Spastic

Tropical Spastic Paraparesis Market to Reach USD 1.3 Billion by 2034
Tropical spastic paraparesis (TSP), also known as HTLV-1-associated myelopathy (HAM/TSP), is a chronic, progressive neurological disorder caused by infection with the human T-cell lymphotropic virus type 1 (HTLV-1). The condition is most prevalent in parts of Africa, the Caribbean, South America, Japan, and the Middle East, with patients experiencing progressive weakness, stiffness, sensory disturbances, and bladder dysfunction due to spinal cord inflammation. Download Full PDF Sample Copy of Market Report @
Tropical Spastic Paraparesis Market: Emerging Trends and New Technologies Resear …
Tropical Spastic Paraparesis Market: Overview Tropical spastic paraparesis (TSP) also called as HTLV-1–associated myelopathy (HAM) is a type of tropical myeloneuropathies caused by the human T-lymphotrophic virus 1 (HTLV-1). Although initially described in tropical countries, TSP has also been found in temperate regions such as southern Japan. HTLV-1 virus belongs to the Retroviridae family, and preferentially infects CD4 lymphoid cells. The virus has been known to cause certain kinds of
06-07-2017 | Health & Medicine
TMR
Tropical Spastic Paraparesis Market: Product and Treatment Landscape
Tropical Spastic Paraparesis Market: Overview Tropical spastic paraparesis (TSP) also called as HTLV-1–associated myelopathy (HAM) is a type of tropical myeloneuropathies caused by the human T-lymphotrophic virus 1 (HTLV-1). Although initially described in tropical countries, TSP has also been found in temperate regions such as southern Japan. HTLV-1 virus belongs to the Retroviridae family, and preferentially infects CD4 lymphoid cells. The virus has been known to cause certain kinds of leukemia
Tropical Spastic Paraparesis Market: Technological Advancements & Global Outlook …
Tropical spastic paraparesis (TSP) also called as HTLV-1–associated myelopathy (HAM) is a type of tropical myeloneuropathies caused by the human T-lymphotrophic virus 1 (HTLV-1). Although initially described in tropical countries, TSP has also been found in temperate regions such as southern Japan. HTLV-1 virus belongs to the Retroviridae family, and preferentially infects CD4 lymphoid cells. The virus has been known to cause certain kinds of leukemia and lymphoma and is
Tropical Spastic Paraparesis Market: Technological Advancements & Global Outlook …
Tropical spastic paraparesis (TSP) also called as HTLV-1–associated myelopathy (HAM) is a type of tropical myeloneuropathies caused by the human T-lymphotrophic virus 1 (HTLV-1). Although initially described in tropical countries, TSP has also been found in temperate regions such as southern Japan. HTLV-1 virus belongs to the Retroviridae family, and preferentially infects CD4 lymphoid cells. The virus has been known to cause certain kinds of leukemia and lymphoma and is
Tropical Spastic Paraparesis Market: Growth Analysis & Projections Forecast to 2 …
Tropical Spastic Paraparesis Market: Overview Tropical spastic paraparesis (TSP) also called as HTLV-1–associated myelopathy (HAM) is a type of tropical myeloneuropathies caused by the human T-lymphotrophic virus 1 (HTLV-1). Although initially described in tropical countries, TSP has also been found in temperate regions such as southern Japan. HTLV-1 virus belongs to the Retroviridae family, and preferentially infects CD4 lymphoid cells. The virus has been known to cause certain kinds of leukemia